Literature DB >> 27158371

AKAP95 promotes cell cycle progression via interactions with cyclin E and low molecular weight cyclin E.

Xiang-Yu Kong1, Deng-Cheng Zhang2, Wen-Xin Zhuang2, Su-Hang Hua1, Yue Dai3, Yang-Yang Yuan2, Li-Li Feng4, Qian Huang2, Bo-Gang Teng2, Xiu-Yi Yu5, Wen-Zhi Liu1, Yong-Xing Zhang2.   

Abstract

AKAP95 in lung cancer tissues showed higher expression than in paracancerous tissues. AKAP95 can bind with cyclin D and cyclin E during G1/S cell cycle transition, but its molecular mechanisms remain unclear. To identify the mechanism of AKAP95 in cell cycle progression, we performed AKAP95 transfection and silencing in A549 cells, examined AKAP95, cyclin E1 and cyclin E2 expression, and the interactions of AKAP95 with cyclins E1 and E2. Results showed that over-expression of AKAP95 promoted cell growth and AKAP95 bound cyclin E1 and E2, low molecular weight cyclin E1 (LWM-E1) and LWM-E2. Additionally AKAP95 bound cyclin E1 and LMW-E2 in the nucleus during G1/S transition, bound LMW-E1 during G1, S and G2/M, and bound cyclin E2 mainly on the nuclear membrane during interphase. Cyclin E2 and LMW-E2 were also detected. AKAP95 over-expression increased cyclin E1 and LMW-E2 expression but decreased cyclin E2 levels. Unlike cyclin E1 and LMW-E2 that were nuclear located during the G1, S and G1/S phases, cyclin E2 and LMW-E1 were expressed in all cell cycle phases, with cyclin E2 present in the cytoplasm and nuclear membrane, with traces in the nucleus. LMW-E1 was present in both the cytoplasm and nucleus. The 20 kDa form of LMW-E1 showed only cytoplasmic expression, while the 40 kDa form was nuclear expressed. The expression of AKAP95, cyclin E1, LMW-E1 and -E2, might be regulated by cAMP. We conclude that AKAP95 might promote cell cycle progression by interacting with cyclin E1 and LMW-E2. LMW-E2, but not cyclin E2, might be involved in G1/S transition. The binding of AKAP95 and LMW-E1 was found throughout cell cycle.

Entities:  

Keywords:  AKAP95; cell cycle; cyclin E; low molecular weight cyclin E; proliferation

Year:  2016        PMID: 27158371      PMCID: PMC4846928     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  37 in total

1.  Deconstructing tick saliva: non-protein molecules with potent immunomodulatory properties.

Authors:  Carlo José F Oliveira; Anderson Sá-Nunes; Ivo M B Francischetti; Vanessa Carregaro; Elen Anatriello; João S Silva; Isabel K F de Miranda Santos; José M C Ribeiro; Beatriz R Ferreira
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

2.  Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.

Authors:  Thomas M Bodenstine; Kedar S Vaidya; Aimen Ismail; Benjamin H Beck; Leah M Cook; Anne R Diers; Aimee Landar; Danny R Welch
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  Cyclin E -- a better prognostic marker for breast cancer than cyclin D?

Authors:  Q P Dou; A B Pardee; K Keyomarsi
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

4.  Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.

Authors:  Jenny Rowe; Rebecca J Greenblatt; Dongmei Liu; Jennifer F Moffat
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

5.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

6.  [Expression of A-kinase anchor protein 95, cyclin E2, and connexin 43 in lung cancer tissue, clinical significance of their expression, and their expression correlation].

Authors:  Yi-de Chen; Xiao-xuan Chen; Li-na Shen; Feng-chao Liang; Ye Ding; Xiu-yi Yu; Mao-qiang Xue; Yong-xing Zhang
Journal:  Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi       Date:  2012-10

7.  Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Authors:  Isabelle Bedrosian; Karen H Lu; Claire Verschraegen; Khandan Keyomarsi
Journal:  Oncogene       Date:  2004-04-08       Impact factor: 9.867

8.  Protein kinase A-anchoring protein AKAP95 interacts with MCM2, a regulator of DNA replication.

Authors:  Turid Eide; Kristin A Taskén; Cathrine Carlson; Gareth Williams; Tore Jahnsen; Kjetil Taskén; Philippe Collas
Journal:  J Biol Chem       Date:  2003-05-09       Impact factor: 5.157

9.  Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Authors:  Said Akli; Ping-Ju Zheng; Asha S Multani; Hannah F Wingate; Sen Pathak; Ning Zhang; Susan L Tucker; Sandy Chang; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  [Relationship between AKAP95, cyclin E1, cyclin D1, and clinicopathological parameters in lung cancer tissue].

Authors:  Su-xian Hu; Xiang-yu Kong; Yang-yang Yuan; Bo-gang Teng; Xue-hong Zhi; Wen-xin Zhuang; Xiu-yi Yu; Wen-zhi Liu; Yong-xing Zhang
Journal:  Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi       Date:  2013-12
View more
  1 in total

1.  Cx43 and AKAP95 regulate G1/S conversion by competitively binding to cyclin E1/E2 in lung cancer cells.

Authors:  Renzhen Chen; Yu Chen; Yangyang Yuan; Xuan Zou; Qian Sun; Hongyan Lin; Xiaoyi Chen; Mingda Liu; Zifeng Deng; Youliang Yao; Dongbei Guo; Yongxing Zhang
Journal:  Thorac Cancer       Date:  2020-04-27       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.